

Systemic Anti-Cancer Therapies / Clinical Trials

Reference Number: F4978
Date of Response: 11/11/2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)	0
Abemaciclib + Fulvestrant	6
Alpelisib + Fulvestrant	0
Atezolizumab +Nab-paclitaxel/Paclitaxel	&<5
Neratinib	0
Olaparib	0
Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)	45
Palbociclib + Fulvestrant	11
Pembrolizumab	0
Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)	17
Ribociclib + Fulvestrant	5
Sacituzumab Govitecan	*<5
Trastuzumab as a single agent or in combination	57
Trastuzumab emtansine	9
Transtuzumab deruxtecan	*<5
Any other active systemic anti-cancer therapy	182

Q2. Does your trust participate in any clinical trials for breast cancer? If so, can you please provide the name of each trial and the number of patients taking part.

ARTemis	5
ATNEC	*<5
Body composition and chemotherapy toxicity in breast cancer (CANDO-3)	*<5
CONCEPT: A Phase II pilot study of 3 weekly Cabazitaxel versus weekly Paclitaxel chemotherapy in the first line treatment of Her2 negative metastatic breast cancer (mBC)	8
DS8201-A-U301, Phase 3, HER2-Positive Breast cancer	*<5
DS8201-A-U302, Phase 3, HER2-Positive breast cancer	*<5
EndoNET	*<5
EPHOS-B	18
FAST-Forward	128

IMPORT HIGH	5
LORIS	11
MAMMO-50	24
MEDICI	13
NCRN250 APHINITY - Traz + Pertuzumab in HER2+ as adjuvant therapy in HER2+ Br Ca	8
NCRN384 KATHERINE: Adjuvant TDM1 in HER 2+ patients with residual disease post neoadjuvant therapy	*<5
OPTIMA	64
Persephone	14
plasmaMATCH	66
POETIC	84
POETIC-A	5
POSNOC.	14
PRIMETIME	78
SUPREMO	6
The MARECA study	5

Please note *≤5. In accordance with section 40 (2) of the Freedom of Information Act 2000, although the Trust holds the information requested, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles.